Polypeptide binding to extracellular domain of epidermal growth factor receptor

US10364293B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10364293-B2
Application numberUS-201515310585-A
CountryUS
Kind codeB2
Filing dateMay 21, 2015
Priority dateMay 23, 2014
Publication dateJul 30, 2019
Grant dateJul 30, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a polypeptide capable of binding specifically to the extracellular domain of epidermal growth factor receptor, a polynucleotide that encodes the polypeptide, an expression vector comprising the polynucleotide, a recombinant microorganism having the expression vector introduced therein, and a method of producing the polypeptide using the recombinant microorganism. The polypeptide according to the present invention can bind to the extracellular domain of epidermal growth factor receptor with a high binding affinity comparable to those of existing monoclonal antibodies that are widely used as targeted therapeutic agents, thereby inhibiting the activity of the epidermal growth factor receptor. The polypeptide is useful for the development of agents for the prevention or diseases associated with overexpression of epidermal growth factor receptor.

First claim

Opening claim text (preview).

The invention claimed is: 1. A polypeptide which has the ability to bind specifically to epidermal growth factor receptor protein and comprises the amino acid sequence of any one of SEQ ID NOS: 6 to 8. 2. The polypeptide of claim 1 , wherein the polypeptide has the ability to bind to the extracellular domain of epidermal growth factor receptor to inhibit the activity of the epidermal growth factor domain. 3. A polypeptide which has the ability to bind specifically to epidermal growth factor receptor protein and comprises the amino acid sequence of any one of SEQ ID NOS: 6 to 8, wherein the polypeptide comprises a fusion of the N-terminus of internalin B protein, a modified repeat module of variable lymphocyte receptor (VLR) protein, and the C-terminus of the VLR protein. 4. A polypeptide which has the ability to bind specifically to epidermal growth factor receptor protein and comprises the amino acid sequence of any one of SEQ ID NOS: 6 to 8, wherein the modified repeat module of the VLR protein comprises the following repeat module pattern: LxxLxxLxLxxN (SEQ ID NO: 10) wherein L is alanine, glycine, phenylalanine, tyrosine, leucine, isoleucine, valine, or tryptophan, N is asparagine, glutamine, seine, cysteine, or threonine, and x is any one of all 20 amino acids. 5. A polynucleotide that encodes the polypeptide of claim 1 . 6. A recombinant vector comprising the polynucleotide of claim 5 . 7. A recombinant microorganism having introduced therein the polynucleotide of claim 5 . 8. A recombinant microorganism having introduced therein the polynucleotide of claim 6 . 9. A method for producing a polypeptide binding specifically to epidermal growth factor receptor protein, comprising the steps of: (i) culturing the recombinant microorganism of claim 7 to produce a polypeptide which has the ability to bind specifically to epidermal growth factor receptor protein and comprises an amino acid sequence of any one of SEQ ID NOS: 6 to 8; and (ii) recovering the polypeptide of claim 1 from the cultured recombinant microorganism or the culture. 10. A composition for preventing or treating cancer, which comprises the polypeptide of claim 1 . 11. The composition of claim 10 , wherein the prevention or treatment of cancer is achieved by the binding of the polypeptide to epidermal growth factor receptor.

Assignees

Inventors

Classifications

  • from vertebrates · CPC title

  • for growth factors; for growth regulators · CPC title

  • having a known sequence of two or more amino acids, e.g. glutathione · CPC title

  • DNA sequences coding for fusion proteins · CPC title

  • C07K19/00Primary

    Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10364293B2 cover?
The present invention relates to a polypeptide capable of binding specifically to the extracellular domain of epidermal growth factor receptor, a polynucleotide that encodes the polypeptide, an expression vector comprising the polynucleotide, a recombinant microorganism having the expression vector introduced therein, and a method of producing the polypeptide using the recombinant microorganism…
Who is the assignee on this patent?
Korea Advanced Inst Sci & Tech
What technology area does this patent fall under?
Primary CPC classification C07K19/00. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).